Results 11 to 20 of about 6,940,670 (314)
Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial.
New England Journal of Medicine, 2020 BACKGROUND There are limited data from randomized trials regarding whether volume-based, low-dose computed tomographic (CT) screening can reduce lung-cancer mortality among male former and current smokers.
H. D. de Koning +23 more
semanticscholar +1 more source
Chinese Journal of Lung Cancer, 2021 Small cell lung cancer (SCLC) is the most malignant lung cancer with the highest mortality. At present, the first-line standard treatment is still based on Etoposide and Platinum chemotherapy.
Zihan QU +5 more
doaj +1 more source
Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer
New England Journal of Medicine, 2018 BACKGROUND First‐line therapy for advanced non–small‐cell lung cancer (NSCLC) that lacks targetable mutations is platinum‐based chemotherapy. Among patients with a tumor proportion score for programmed death ligand 1 (PD‐L1) of 50% or greater ...
L. Gandhi +28 more
semanticscholar +1 more source
Lung cancer immunotherapy: progress, pitfalls, and promises
Molecular Cancer, 2023 Lung cancer is the primary cause of mortality in the United States and around the globe. Therapeutic options for lung cancer treatment include surgery, radiation therapy, chemotherapy, and targeted drug therapy.
Aritraa Lahiri +7 more
semanticscholar +1 more source
EGFR-TKI ADR Management Chinese Expert Consensus
Chinese Journal of Lung Cancer, 2019 ErbB receptor tyrosine kinase inhibitors (EGFR-TKI), gefitinib, erlotinib, icotinib and aftinib, which are approved as a frontline treatment for patients with non-small cell lung cancer (NSCLC) who have tumors harboring EGFR mutations in China.
Chinese Society of Lung Cancer, Chinese Anti-Cancer Association
doaj +1 more source
Thoracic Cancer, 2021 Background Lung cancer, mainly non‐small cell lung cancer (NSCLC), is one of the leading causes of death worldwide. Currently, chemotherapy is still the most significant treatment strategy for NSCLC.
Jinghao Liu +11 more
doaj +1 more source
Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer
Frontiers in Oncology, 2021 The clinical application of immunotherapy is the milestone of cancer treatment. However, some patients have bad reaction. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple cancer cells and is associated with poor prognosis.
Dan Pu +8 more
doaj +1 more source
Chinese Journal of Lung Cancer, 2023 Erratum: Study on the Biological Function of Abemecilib in Inhibiting the Proliferation, Invasion and Migration of Small Cell Lung Cancer with High c-Myc Expression Guo JJ, Mu D, Yu WW, et al. Zhongguo Fei Ai Za Zhi, 2023, 26(2): 105-112.
Editorial Office of Chinese Journal of Lung Cancer
doaj +1 more source
Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement.
Journal of the American Medical Association (JAMA), 2021 Importance Lung cancer is the second most common cancer and the leading cause of cancer death in the US. In 2020, an estimated 228 820 persons were diagnosed with lung cancer, and 135 720 persons died of the disease.
A. Krist +18 more
semanticscholar +1 more source
Screening for lung cancer: 2023 guideline update from the American Cancer Society
Ca, 2023 Lung cancer is the leading cause of mortality and person‐years of life lost from cancer among US men and women. Early detection has been shown to be associated with reduced lung cancer mortality.
Andrew M.D. Wolf +14 more
semanticscholar +1 more source